Biodel (BIOD) : Traders are bullish on Biodel (BIOD) as it has outperformed the S&P 500 by a wide margin of 35.76% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 29.98%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 29.89% in the last 1 week, and is up 40.32% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 29.27% and the 50-Day Moving Average is 27.72%. Biodel Inc. is up 6.1% in the last 3-month period. Year-to-Date the stock performance stands at 27.94%.
Biodel (NASDAQ:BIOD): On Fridays trading session , Opening price of the stock was $0.455 with an intraday high of $0.4701. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.43. However, the stock managed to close at $0.435, a loss of 3.33% for the day. On the previous day, the stock had closed at $0.45. The total traded volume of the day was 1,066,414 shares.
Biodel Inc. is a specialty pharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs to improve their therapeutic profiles. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia or low concentrations of blood glucose. The Company is also developing insulin formulations for Type 1 and Type 2 diabetes patients. The Companys product pipeline includes RHI-Based Ultra-Rapid-Acting Insulin, Analog-Based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon.